Sung-Chun Tang1, Shin-Joe Yeh1, Li-Kai Tsai1, Chaur-Jong Hu1, Li-Ming Lien1, Giia-Sheun Peng1, Wei-Shiung Yang1, Hung-Yi Chiou1, Jiann-Shing Jeng2. 1. From the Stroke Center and Department of Neurology (S.-C.T., S.-J.Y., L.-K.T., J.-S.J.), Department of Internal Medicine (W.-S.Y.), National Taiwan University Hospital; the Department of Neurology (C.-J.H.), Taipei Medical University Hospital and Shuang Ho Hospital; the Department of Neurology (L.-M.L.), Shin Kong Wu Ho-Su Memorial Hospital; the Department of Neurology (G.-S.P.), Tri-Service General Hospital; and the School of Public Health (H.-Y.C.), Taipei Medical University, Taipei, Taiwan. 2. From the Stroke Center and Department of Neurology (S.-C.T., S.-J.Y., L.-K.T., J.-S.J.), Department of Internal Medicine (W.-S.Y.), National Taiwan University Hospital; the Department of Neurology (C.-J.H.), Taipei Medical University Hospital and Shuang Ho Hospital; the Department of Neurology (L.-M.L.), Shin Kong Wu Ho-Su Memorial Hospital; the Department of Neurology (G.-S.P.), Tri-Service General Hospital; and the School of Public Health (H.-Y.C.), Taipei Medical University, Taipei, Taiwan. jsjeng@ntu.edu.tw.
Abstract
OBJECTIVE: To investigate the expression patterns of 2 soluble isoforms of receptor for advanced glycation end-product (RAGE), including endogenous secretory RAGE (esRAGE) and cleaved RAGE (cRAGE), and their associations with outcome in acute ischemic stroke (IS). METHODS: Acute IS patients (n = 106) and age- and sex-matched controls (n = 150) were recruited. Plasma levels of total soluble RAGE (sRAGE) and esRAGE in patients at <48 hours and 48-72 hours after IS and in controls were measured by ELISA. The level of cRAGE was calculated by subtracting the level of sRAGE from that of esRAGE. Poor outcome was defined as modified Rankin Scale score >2 at 3 months after stroke. RESULTS: The plasma levels of cRAGE were significantly higher and correlated to those of esRAGE (p < 0.001). The plasma levels of esRAGE and cRAGE were both significantly higher in IS patients <48 hours and 48-72 hours after onset than in controls, but only level of cRAGE at <48 hours was independently associated with poor outcome after adjusting for clinical variables (odds ratio 2.44; 95% confidence interval 1.16-5.16; p = 0.019). CONCLUSION: The plasma level of cRAGE at <48 hours after IS, rather than esRAGE, is a significant predictor of acute IS outcome.
OBJECTIVE: To investigate the expression patterns of 2 soluble isoforms of receptor for advanced glycation end-product (RAGE), including endogenous secretory RAGE (esRAGE) and cleaved RAGE (cRAGE), and their associations with outcome in acute ischemic stroke (IS). METHODS: Acute IS patients (n = 106) and age- and sex-matched controls (n = 150) were recruited. Plasma levels of total soluble RAGE (sRAGE) and esRAGE in patients at <48 hours and 48-72 hours after IS and in controls were measured by ELISA. The level of cRAGE was calculated by subtracting the level of sRAGE from that of esRAGE. Poor outcome was defined as modified Rankin Scale score >2 at 3 months after stroke. RESULTS: The plasma levels of cRAGE were significantly higher and correlated to those of esRAGE (p < 0.001). The plasma levels of esRAGE and cRAGE were both significantly higher in IS patients <48 hours and 48-72 hours after onset than in controls, but only level of cRAGE at <48 hours was independently associated with poor outcome after adjusting for clinical variables (odds ratio 2.44; 95% confidence interval 1.16-5.16; p = 0.019). CONCLUSION: The plasma level of cRAGE at <48 hours after IS, rather than esRAGE, is a significant predictor of acute IS outcome.
Authors: Tina E Brinkley; Xiaoyan Leng; Barbara J Nicklas; Stephen B Kritchevsky; Jingzhong Ding; Dalane W Kitzman; W Gregory Hundley Journal: Metabolism Date: 2017-02-10 Impact factor: 8.694
Authors: Edwin R Miranda; Vikram S Somal; Jacob T Mey; Brian K Blackburn; Edward Wang; Sarah Farabi; Kristian Karstoft; Ciaran E Fealy; Sangeeta Kashyap; John P Kirwan; Laurie Quinn; Thomas P J Solomon; Jacob M Haus Journal: Am J Physiol Endocrinol Metab Date: 2017-08-15 Impact factor: 4.310
Authors: Michelle J Lim; Matt S Zinter; Lucia Chen; Kayley Man Yee Wong; Anoopindar Bhalla; Kinisha Gala; Mona Guglielmo; Mustafa Alkhouli; Leanna L Huard; Mark R Hanudel; Sitaram Vangala; Andreas Schwingshackl; Michael Matthay; Anil Sapru Journal: Crit Care Med Date: 2021-10-25 Impact factor: 9.296
Authors: E R Miranda; K N Z Fuller; R K Perkins; C M Kroeger; J F Trepanowski; K A Varady; J M Haus Journal: Nutr Metab Cardiovasc Dis Date: 2018-08-02 Impact factor: 4.222
Authors: Kelly N Z Fuller; Edwin R Miranda; John P Thyfault; Jill K Morris; Jacob M Haus Journal: Mediators Inflamm Date: 2018-02-22 Impact factor: 4.711